Newsbenzinga
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer
· Published
Article summary
Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemotherapy in advanced endometrial cancer.
An excerpt from the original article.
Comments —
Loading comments…